CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2021 Earnings Presentation
20 slides from CelLBxHealth's earnings presentation, Sep 30, 2021
Slide 1: Interim results for the six months ended 30 June 2021
Interim results for the six months ended 30 June 2021 Andrew Newland and Ian Griffiths 30 September 2021
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Liquid biopsy - improving patient outcomes and reducing healthcare costs
Liquid biopsy - improving patient outcomes and reducing healthcare costs Parsortix® cassette “ANGLE’s mission is to enable personalized cancer care by providing the best sample of the patient’s cancer from a simple blood test. Product-based solution for simple, effective, affordable repeat testing o
Slide 4: First Half Highlights
First Half Highlights Significant progress against key strategic objectives • FDA review of De Novo Submission for Class II • Post period end, capital raise of £20 million well clearance in metastatic breast cancer progressing as supported by new and existing shareholders in UK and expected United S
Slide 5: Financial Results for six months ended 30 June 2021
Financial Results for six months ended 30 June 2021 Six months ended Six months ended 30 June 2021 30 June 2020* Comments £’000 £’000 Statement of Comprehensive Income • Revenue increased by 26% Revenue and grant income 312 268 • Gross margin at 74% Cost of sales (77) (59) Gross profit and grant inc
Slide 6: Commercialization process
Commercialization process Leveraged Research ANGLE ANGLE Leveraged & Development Development Process Clinical Laboratories Commercialization Accelerator and Demonstrator 46 peer-reviewed publications Assay Development Pharma Services CROs 29 independent cancer centres Clinical Validation LDTs: Ovari
Slide 7: FDA clearance: regulatory response anticipated in H2 2021
FDA clearance: regulatory response anticipated in H2 2021 • FDA De Novo Submission for Class II clearance in metastatic breast cancer submitted 25 September 2020 – 400 subject clinical study with four leading United States cancer centres – over 15,000 samples and 400 reports and technical documents
Slide 8: Clinical laboratories established in UK and United States
Clinical laboratories established in UK and United States • Pharma services business growing – first pharma services contracts signed including first assay development contract signed post period end – initial capacity intended for 50,000 samples p.a. at $1,000 baseline price and up to $2,000 per sa
Slide 9: Pharma services – immunotherapy PD-L1 biomarker assay c. US $1.6 billion p.a. global market
Pharma services – immunotherapy PD-L1 biomarker assay c. US $1.6 billion p.a. global market Price per sample Mean # of Number of Number of Number of samples Addressable number Addressable market p.a. PD-L1 Drug Trials (US$) patients per trial trials patients in trials per patient of samples (US$) 1
Slide 10: First pharma services contracts secured
First pharma services contracts secured • ANGLE’s pharma services business launched in Q1 2021, addressing a new market for use of the Parsortix system in cancer drug trials. Sales processes being developed to demonstrate capability, quality systems, sample handling and reporting • Contracts already
Slide 11: Ovarian cancer pelvic mass triage test clinical study in progress
Ovarian cancer pelvic mass triage test clinical study in progress • 5-10% of women suffer from abnormal pelvic mass • Over 200,000 women p.a. in US alone have surgery for pelvic mass with advance diagnosis of ovarian cancer a critical unmet medical need • Two 200 patient studies already completed “T
Slide 12: Ovarian cancer clinical tests c. US $1.3 billion p.a. market (United States only)
Ovarian cancer clinical tests c. US $1.3 billion p.a. market (United States only) Reimbursement Number of patients Number of tests Addressable number of Addressable market Target market Application potential (US$) p.a. per patient p.a. tests p.a. p.a. (US$) entry 1 Pelvic mass surgery triage $1,000
Slide 13: Prostate cancer next major investment focus
Prostate cancer next major investment focus • 1 in 8 men will be diagnosed with prostate cancer – in the United States alone, estimated 250,000 new cases (2021) and 3.2 million (2018) living with prostate cancer • 1 million prostate biopsies undertaken each year in United States – despite advances i
Slide 14: Prostate cancer clinical tests c. US $6.7 billion p.a. market (United States only)
Prostate cancer clinical tests c. US $6.7 billion p.a. market (United States only) Reimbursement Number of Number of tests Addressable number Addressable market per Target market Application potential (US$) patients p.a. per patient p.a. of tests p.a. annum (US$) entry 1 High risk screening $1,000 1
Slide 15: Growing body of evidence: Leveraged R&D strategy identifying new applications
Growing body of evidence Leveraged R&D strategy identifying new applications • Translational research market $50 million p.a. • FDA clearance expected to help CTC clusters 39 CTC culturing published in Parsortix become the CTC system of choice Metastatic brain cancer 10 high impact journals 29 studi
Slide 16: Commercialisation aim to enable entire industry
Commercialisation aim to enable entire industry Product-based commercialisation delivers numerous opportunities • Medtech companies to expand revenue opportunities for installed base – expand from one-off tissue biopsy to repeat liquid biopsy tests • Pharma companies to enable precision medicines –
Slide 17: Near term milestones
Near term milestones Leading cancer centres with original research and peer-reviewed publications using ANGLE’s Parsortix system (selection) • Expanding pharma services business • FDA clearance: regulatory response anticipated in H2 2021* • Ovarian cancer headline results expected Q4 2021 • Seeking
Slide 18: Questions and answers
Questions and answers © ANGLE plc 2021 18
Slide 19: Investment Highlights
Investment Highlights ANGLE’s Parsortix® system is a simple blood test for personalised cancer Large scale clinical studies in ovarian cancer significantly out-performed care, which harvests viable intact cancer cells (CTCs) for analysis existing standard of care • unique patented microfluidic appro
Slide 20: ANGLE plc contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom ANGLE North America Inc 5100 Campus Drive Suite 120 Plymouth Meeting PA 19462 USA ANGLE Biosciences Inc 50 Ronson Drive, Suite 105 Toronto Ontario M9W 1B3 Canada www.angleplc.com 20